Improving acute kidney injury diagnostic precision using biomarkers

Area of Science:

• Nephrology
• Biomarker Discovery
• Clinical Diagnostics

Background:

• Acute kidney injury (AKI) is prevalent in hospitalized patients, leading to significant morbidity and mortality.
• Current methods like serum creatinine and urine output monitoring have limitations in sensitivity, specificity, and practicality, especially in children.
• Effective AKI management necessitates early identification and prediction, as no specific therapeutic interventions exist to reverse established AKI.

Purpose of the Study:

• To review and discuss clinically available biomarkers for acute kidney injury (AKI).
• To explore how these biomarkers aid in delineating distinct AKI phenotypes.
• To highlight the prognostic and therapeutic implications of identifying AKI phenotypes.

Main Methods:

• Review of existing literature on clinically available AKI biomarkers.
• Analysis of studies investigating Plasma Cystatin C, urine neutrophil gelatinase associated lipocalin (NGAL), and the urinary product of tissue inhibitor metalloproteinase (TIMP-2) and insulin growth factor binding protein-7 (IGFBP7).
• Examination of biomarker utility across diverse patient populations and clinical settings for AKI prediction.

Main Results:

• Plasma Cystatin C, urine NGAL, and the TIMP-2/IGFBP7 complex are clinically accessible biomarkers for AKI.
• These biomarkers have demonstrated potential in predicting AKI across various age groups and clinical scenarios.
• Integration of these biomarkers can help define unique AKI phenotypes.

Conclusions:

• Clinically available biomarkers offer a promising approach to improve the early detection and prediction of AKI.
• The use of biomarkers like Cystatin C, NGAL, and TIMP-2/IGFBP7 can aid in classifying AKI phenotypes, potentially guiding treatment and improving patient outcomes.
• Further research and validation are essential to fully leverage these biomarkers in clinical practice for AKI management.